Arrowhead PharmaceuticalsARWR
Buy moreBuy more at today's $47, already under our buy price.
- 4 good· Wider margin
- 4 to watch· Below 50-day
$47.43−1.93 (−3.91%)
Price at 3:03 PM ET
After hours · opens in 17h 23mNext open: Friday, Nov 13, 9:30 AM ETNYSE · Healthcare · Health Care · Mid-size company
The price we'd buy ARWR at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- Analysts' forecast on the Nasdaq earnings calendar
- From the 10-Q for the quarter to Jun 30, reported Aug 4
- Yahoo Finance daily closes to Nov 11
Any one could move it to Keep
Next report · Today
over$1.59
loss per share
below8%
sales growth
Compared with the S&P 500
14 points
worse in one day
30 points
worse in five trading days
+14.3% in a yearsince Nov 11, 2025
The news behind our call
UK approval meets a sharp reset before earnings
UK approval gives Arrowhead’s drug development story a concrete regulatory milestone.
What changed
Nov 12
today
ARWR reports earnings after the market closes
Analysts expect $-1.59 a share.
Overview
In plain numbers
- Revenue grew 16.8% from a year earlier, to $669.5M in the last twelve months.
- It loses 34 cents on every revenue dollar at the operating line, up from a loss of $1.08 in FY 2021.
- It burned $75.1M of free cash in the last twelve months.
- It holds $1.6B in cash and investments against $1.4B of debt, which leaves $218.5M of net cash.
Key figures
- Revenue (TTM)
- $670M
- Revenue growth, 1 year
- +16.8%
- Net income
- −$320M
- EPS (diluted)
- −$2.28
- Gross margin
- 100.0%
- Operating margin
- -33.8%
- Return on equity
- -55.2%
- Return on capital
- -101.1%
- Debt / equity
- 2.96
- Current ratio
- 5.90
- Buyback yield
- -7.74%
Key facts
- Company value
- $8.2B
- Today's range
- 46.9848.99
- Past year's range
- 38.0989.59
- Yesterday's close
- $49.36
- Swings vs the market
- 1.3×about the same
- Next earnings
- Nov 12today